3Vote!
Medical News Today (Free subscription) | yesterday
Novavax, Inc. (Nasdaq: NVAX) reported favorable initial results from the first stage of a two-stage pivotal Phase II study evaluating the safety and immunogenicity of the company's 2009 H1N1 virus-like particle (VLP) pandemic influenza vaccine. Novavax is conducting this study in collaboration with Avimex Laboratories of Mexico to support registration of the vaccine in Mexico and...
+Vote!
Volume Spike Investor (Free subscription) | 12/02/2009
Novavax, Inc. (NASDAQ: NVAX) is trading up again on swine flu or H1N1 news. The company issued a press release showing positive clinical results from a pivotal study of H1N1 influenza vaccine in Mexico. At 8:21 AM EST we have seen 319,000 shares trade hands and the stock is up 7.1% at $3.44. Average volume [...]
5Vote!
The Washington Business Journal (Free subscription) | 12/02/2009
Novavax Inc. announced Wednesday that its H1N1 flu vaccine proved safe and effective in a study conducted in Mexico. The news sent shares of the Rockville biotech higher. (NVAX)
4Vote!
PR News Wire (Free subscription) | 12/02/2009
ROCKVILLE, Md., Dec. 2 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) today reported favorable initial results from the first stage of a two-stage pivotal Phase II study evaluating the safety and immunogenicity of the company's 2009 H1N1 virus-like particle (VLP) pandemic influenza vaccine. Novavax is conducting this study in collaboration with Avimex Laboratories of Mexico...
3Vote!
Medical News Today (Free subscription) | 12/01/2009
Novavax, Inc. (Nasdaq: NVAX) announced it has completed enrollment in the Phase II clinical study of its trivalent seasonal influenza (2008/2009 recommended strains) VLP vaccine candidate in healthy adults 60 years of age or older (older adults).
5Vote!
Volume Spike Investor (Free subscription) | 11/30/2009
Novavax, Inc. (NASDAQ: NVAX) may show how little key impact news there is, but it is the top mover today in percentage terms seen. At 8:28 AM EST we have seen 75,000 shares trade (versus 6 million average) and the stock is up 6.6% at $3.20. This is on news that it has completed enrollment [...]
5Vote!
PR News Wire (Free subscription) | 11/30/2009
ROCKVILLE, Md., Nov. 30 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced today that the company will be presenting at the 21st Annual Health Care Conference 2009 on December 2, 2009 at 12:30 pm local time at The New York Palace, New York. Novavax will provide an overview of the company's business strategy, research and development...
4Vote!
Market Watch (Free subscription) | 11/30/2009
BOSTON (MarketWatch) -- Novavax Inc. said early Monday that if current Phase II testing for its new seasonal flu vaccine is successful, Phase III testing could start as early as 2010. Novavax said Monday that it has completed enrollment for a Phase II trial of its seasonal flu vaccine candidate. The company is also testing a vaccine for the prevention of the H1N1 virus. The vaccines...
4Vote!
PR News Wire (Free subscription) | 11/30/2009
ROCKVILLE, Md., Nov. 30 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) announced today it has completed enrollment in the Phase II clinical study of its trivalent seasonal influenza (2008/2009 recommended strains) VLP vaccine candidate in healthy adults 60 years of age or older (older adults). This randomized, double-blind, active-controlled study is comparing the safety, tolerability...
5Vote!
The Washington Business Journal (Free subscription) | 11/30/2009
Novavax Inc. has begun clinical trials of its seasonal influenza vaccine with older patients. (NVAX)
3Vote!
Radon Mitigation Pittsburgh (Free subscription) | 12/02/2009
( EMAILWIRE.COM , December 02, 2009 ) Dallas, TX - Cell Therapeutics, Inc. (NASDAQ:CTIC) climbed 5.73% to $1.09. The stock hit an intraday high and an intraday low of $1.09 and $1.05 respectively. In the last six months the stock went down over 48%. Cell Therapeutics, Inc. (Cell Therapeutics) develops, acquires and commercializes treatments for cancer. The Company's research, development,...
4Vote!
Stock Market Analysis (Free subscription) | 12/02/2009
Below is a list of some of the largest stock gainers and losers so far in pre market for December 2, 2009. Check out my Hot Stocks to Watch page for the latest updates. Pre Market Stock Gainers - 12/2/09 Dyax Corp. (DYAX) - Dyax gets FDA marketing nod on genetic disease drug Santarus Inc. (SNTS) - Santarus Announces FDA Approval of Schering-Plough HealthCare Products' ZEGERID OTC G-III Apparel...
+Vote!
EconoSpeak (Free subscription) | 12/02/2009
... some European countries, while other countries report sharp increases. 2009 – November 17th. Novavax, Inc., announced it will begin studies in Mexico on a new vaccine against H1N1. Initially, about 1,000 people will participate. 2009 – November 12th. Headlines state CDC officials calculate over 4,000 deaths (as opposed to about 1,200 currently reported) are due to H1N1...
8Vote!
24/7 Wall St. (Free subscription) | 12/02/2009
These are this Wednesday’s top day trader and active trader alert stocks with links to VSInvestor.com for more detailed data and analysis: Diedrich Coffee Inc. (NASDAQ: DDRX) is up again as the buyout wars continue from Green Mountain Coffee Roasters (NASDAQ: GMCR) and Peet’s Coffee & Tea (NASDAQ: PEET). Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) is active again, [...]...
8Vote!
24/7 Wall St. (Free subscription) | 11/30/2009
These are this Monday’s top day trader and active trader alert stocks. We have more details on the gains and ranges with added color via a link through to VSInvestor.com for each stock: Novavax, Inc. (NASDAQ: NVAX) is up 6.6% and was actually the top percentage gainer in early indications. Baidu, Inc. (NASDAQ: BIDU) is down less [...]
